Arch pharmalabs Limited
+100 % 1 MAbout Arch pharmalabs Limited
A Comprehensive Overview of Price & Journey
Understanding Arch pharmalabs Limited Inception and Growth
Overview
Arch Pharmalabs Limited is a prominent Indian pharmaceutical company which is specialized in the manufacturing of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. The company is headquartered in Mumbai, Maharashtra, and operates multiple manufacturing facilities that adhere to international regulatory standards. Arch Pharmalabs is known for its focus on quality, innovation, and customer satisfaction. It supplies APIs and intermediates to leading pharmaceutical companies globally.
Products & Services
Arch Pharmalabs offers a comprehensive range of products and services, including:
-
Active Pharmaceutical Ingredients (APIs)
-
Advanced Intermediates
-
Contract Manufacturing Services
-
Custom Synthesis
Board of Directors
-
Ajit Kamath - Executive Chairman and Managing Director
-
Rajendra Kaimal - Executive Director
IPO Details
Arch Pharmalabs Limited is not a publicly listed company. Consequently, there have been no announcements regarding an Initial Public Offering (IPO), and there is no official Arch Pharmalabs Ltd share price available. However, continued interest in the company’s performance and prospects has led many to search for updates on the Arch Pharmalabs Ltd share price, anticipating any future developments in its listing status.
About Arch pharmalabs Limited
IPO Details, Price movement
Performance Highlights 2023-2024
-
Revenue from Operations increased from ₹1303 crore in FY2022- 23 to ₹1337 crore in FY2023- 24.
-
Profit Before Tax increased from ₹58.5 crore in FY2022- 23 to ₹124.6 crore in FY2023- 24.
-
Net Profit (PAT) increased from ₹58.7 crore in FY2022- 23 to ₹124.6 crore in FY2023- 24.
-
Cash flow from Operating Activities was INR 115 crore in FY23 and became INR 42.5 crore in FY24.
-
Net Cash Used in Investing Activities was INR 10.67 crore in FY23, whereas it became INR 1.39 crore in FY24.
-
Net cash used in Financing Activities was INR 105 crore in FY23, whereas it became INR 41 crore in FY24.
Fundamentals
Financials
| P&L Statement | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Revenue | - | - | 1308.98 | 1341.00 |
| Other Income | - | - | 5.11 | - |
| COGS | - | - | 1052.00 | 1062.00 |
| Gross Profit | - | - | 257.00 | 279.00 |
| Total Expense | - | - | 79.00 | 100.00 |
| EBIDTA | - | - | 177.00 | 180.00 |
| D&A | - | - | 98.00 | 35.00 |
| EBIT | - | - | 152.00 | 157.00 |
| Interest Expense | - | - | 98.00 | 35.00 |
| PBT | - | - | 52.00 | 122.00 |
| TAX | - | - | - | - |
| PAT | - | - | 52.00 | 122.00 |
| Diluted EPS | - | - | 3.42 | 7.80 |
| Basic EPS | - | - | 3.42 | 7.80 |
| Total income | 0.00 | 0.00 | 1,314.09 | 1,341.00 |
ASSETS
| CURRENT ASSETS | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Cash and Cash Equivalents | - | - | 2.77 | 2.77 |
| Trade Payables | - | - | 314.03 | 698.06 |
| Inventory | - | - | 698.90 | 681.25 |
| Other Current Assets | - | - | 332.27 | 131.27 |
| Total Current Assets | 0.00 | 0.00 | 1,347.97 | 1,513.35 |
| NON CURRENT ASSETS | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Plant Property and Equipment | - | - | 876.27 | 810.29 |
| Long Term Investment | - | - | 15.56 | 13.06 |
| Other Non Current Assets | - | - | 78.38 | 78.79 |
| TOTOAL NON CURRENT ASSSETS | 0.00 | 0.00 | 970.21 | 902.14 |
| Total Assets | 0.00 | 0.00 | 2,318.18 | 2,415.49 |
|---|
| CURRENT LIABILITES | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| TRADW Payable | - | - | 337.02 | 226.15 |
| Other Current Liab | - | - | 692.02 | 696.96 |
| Total Current Liab | 0.00 | 0.00 | 1,029.04 | 923.11 |
| NON CURRENTLIABILITIES | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Long Term Debt | - | - | 668.98 | 6641.88 |
| Deffered Tax Liab | - | - | - | - |
| Other Non Current Liab | - | - | 13.44 | 12.69 |
LIABILITIES
| EQUITY | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Share Capital | - | - | 151.92 | 156.48 |
| Reserves And Surplus | - | - | 432.68 | 657.63 |
| Other Equity | - | - | 22.12 | 23.69 |
| Retained Earnings | - | - | - | - |
| share Equity | 0.00 | 0.00 | 606.72 | 837.80 |
| Total Liabilities | 0.00 | 0.00 | 1,289.14 | 7,492.37 |
|---|
| CASH FLOW STAT | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Cash Flow from operating | - | - | 115.33 | 42.49 |
| Cash Flow from financing | - | - | -105.16 | -41.10 |
| Cash Flow from investing | - | - | -10.68 | -1.39 |
| Net cash flow | 0.00 | 0.00 | -0.51 | 0.00 |
Revenue Growth
PAT Growth %
EPS Growth %
TOTAL ASSETS Growth %
QUICK RATIO Growth %
LONG TERM DEBT TO EQUITY RATIO Growth %
Shareholding Pattern
2025
| Name | Designation | Share % |
|---|---|---|
| Arch Impex Prvate Limited | NA | 25.24% |
| JM Financial Asset Reconstruction Company Limited | NA | 35.41% |
| Arch Pharmachem Limited | NA | 13.54% |
| Others | NA | 25.81% |
Events
| Name | Date | Details |
|---|---|---|
| No events available. | ||
Frequently Asked Questions
The lockin period is of 6 months for pre-ipo investors i.e. they cannot sell their shares for 6 months after they get listed. However, they can definitely sell the shares in pre-ipo market before they get listed.
With BharatInvest, you can now invest in unlisted/pre-ipo shares with as low as 25-50k depending upon the share.
- 1. You can download the NSDL or CDSL application and login into the account and check whether the shares have been credited or not.
2. Credit of Unlisted Shares/Pre-IPO shares can be checked in brokers application as well but it takes T+2 days to show the shares
- The value of share in unlisted space is determined in the same way as it is done in listed market. Demand and supply decide the price of any share. If the demand more than the supply, then the prices of the share increases and vice versa.
- When a new shares is introduces in the unlisted space, the value of the company is decided upon the last funding raised by company. If the company hasn’t raised any funding in the past, then the valuation is decided upon the fundamentals of the company.
- A Public Unlisted Shares Is Not Listed on Stock Exchange, Where as a Listed Public Company Is Listed On Stock Exchange Such As BSE Or NSE For Trading Of Shares.
- If you sell your shares within 2 years, then you will have to pay Short-term Capital gain on unli sted shares. Short-Term Capital Gain is added in your Income. So, as per individual tax slab you need to pay capital gain tax.
- If you sell your shares after 2 years, then you will have to pay Long-term Capital gain on unlisted shares LTCG is 12.5% without indexation benefits.
- After listing of shares, the unlisted shares which you have bought through unlisted market, will be taxed at listed rates, if sold through exchange. So, taxes of listed market will be applicable. And, to calculate holding time, for determining LTCG or STCG, the purchase date of unlisted shares will be applicable.
- Absoluetly NOT! Grey market is all about speculation relation to open price, subscription rate etc. And does not include physical delivery of shares. Whereas in pre ipo market you get to invest in shares much before the ipo too and it involves physical delivery of shares. It is compeletly legal and does not include any such speculation.
- Existing stakeholders, promoters or employees who have equity shares of an unlisted company and early investors who wish to get value of their investment.
- Yes, investing in unlisted shares is undoubtedly legal in India. The trading takes place in the over-the-counter market.